Oncotarget

Vol 3, No 6

June 2012

View Archive »

Order a Reprint

About The Cover

An example of invasion ex vivo: 3D reconstruction of optical projection tomography of a representative ER+ HER2- tumour. See Katz et al.

Table of Contents

Editorial

Destroying c-Jun Messenger: New Insights into Biological Mechanisms of DNAzyme Function

Destroying c-Jun Messenger: New Insights into Biological Mechanisms of DNAzyme Function

https://doi.org/10.18632/oncotarget.549

Levon M. Khachigian, Hong Cai, Fergal J. Moloney, Christopher R. Parish, Beng H. Chong, Roland Stocker, Ross St.C. Barnetson,  and Gary M. Halliday
594-595
PDF  |  HTML  |  Order a Reprint

Research Perspectives

Cyclotherapy: opening a therapeutic window in cancer treatment

Cyclotherapy: opening a therapeutic window in cancer treatment

https://doi.org/10.18632/oncotarget.524

Ingeborg M.M. van Leeuwen
596-600
Abstract  |  PDF  |  HTML  |  Order a Reprint

Wt p53 impairs response to chemotherapy: make lemonade to spare normal cells

Wt p53 impairs response to chemotherapy: make lemonade to spare normal cells

https://doi.org/10.18632/oncotarget.548

Mikhail V. Blagosklonny
601-607
Abstract  |  PDF  |  HTML  |  Order a Reprint

Research Papers

Targeting of Rac GTPases blocks the spread of intact human breast cancer

Targeting of Rac GTPases blocks the spread of intact human breast cancer

https://doi.org/10.18632/oncotarget.520

Elad Katz, Andrew H. Sims, Duncan Sproul, Helen Caldwell, J. Michael Dixon, Richard R. Meehan,  and David J. Harrison
608-619
Abstract  |  PDF  |  HTML  |  Supplementary Information  |  Order a Reprint

Clinical utility of gene-expression profiling for tumor-site origin in patients with metastatic or poorly differentiated cancer: impact on diagnosis, treatment, and survival

Clinical utility of gene-expression profiling for tumor-site origin in patients with metastatic or poorly differentiated cancer: impact on diagnosis, treatment, and survival

https://doi.org/10.18632/oncotarget.521

J Scott Nystrom, John C. Hornberger, Gauri R. Varadhachary, Richard J. Hornberger, Hialy R. Gutierrez, W. David Henner, Shawn H. Becker, Mahul B. Amin,  and Michael G. Walker
620-628
Abstract  |  PDF  |  HTML  |  Order a Reprint

Computer-Based Identification of a Novel LIMK1/2 Inhibitor that Synergizes with Salirasib to Destabilize the Actin Cytoskeleton

Computer-Based Identification of a Novel LIMK1/2 Inhibitor that Synergizes with Salirasib to Destabilize the Actin Cytoskeleton

https://doi.org/10.18632/oncotarget.525

Efrat Mashiach Farkash, Roni Rak, Galit Elad-Sfadia, Roni Haklai, Shmuel Carmeli, Yoel Kloog,  and Haim Wolfson
629-639
Abstract  |  PDF  |  HTML  |  Order a Reprint

A composite polymer nanoparticle overcomes multidrug resistance and ameliorates doxorubicin-associated cardiomyopathy

A composite polymer nanoparticle overcomes multidrug resistance and ameliorates doxorubicin-associated cardiomyopathy

https://doi.org/10.18632/oncotarget.543

Dipankar Pramanik, Nathaniel R Campbell, Samarjit Das, Sonal Gupta, Venugopal Chenna, Savita Bisht, Polina Sysa-shah, Djahida Bedja, Collins Karikari, Charles Steenbergen, Kathleen L. Gabrielson, Amarnath Maitra,  and Anirban Maitra
640-650
Abstract  |  PDF  |  HTML  |  Supplementary Information  |  Order a Reprint

Sox9 is required for prostate development and prostate cancer initiation

Sox9 is required for prostate development and prostate cancer initiation

https://doi.org/10.18632/oncotarget.531

Zhenhua Huang, Paula J. Hurley, Brian W. Simons, Luigi Marchionni, David M. Berman, Ashley E. Ross,  and Edward M. Schaeffer
651-663
Abstract  |  PDF  |  HTML  |  Supplementary Information  |  Order a Reprint


Copyright © 2017 Impact Journals
Impact Journals is a registered trademark of Impact Journals, LLC